Currently, AD diagnostics are based on the assessment of dementia symptoms supported by the AD-associated biomarkers amyloid Aβ and tau and phosphorylated tau (p-tau/tau), whose levels are measured in cerebrospinal fluid (CSF) with immunoassays and imaging methods in the brains of living patients1,2. The gene discussed is MAPT; the disease is dementia.